RAFFA WEALTH MANAGEMENT, LLC’s Neurocrine Biosciences NBIX Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.04K	Buy	24 +4	+20%	+$593	﹤0.01%	641
2026 Q1	$2.63K	Buy	20 +1	+5%	+$133	﹤0.01%	680
2025 Q4	$2.69K	Hold	19	–	–	﹤0.01%	668
2025 Q3	$2.67K	Hold	19	–	–	﹤0.01%	635
2025 Q2	$2.39K	Hold	19	–	–	﹤0.01%	650
2025 Q1	$2.1K	Hold	19	–	–	﹤0.01%	616
2024 Q4	$2.59K	Hold	19	–	–	﹤0.01%	600
2024 Q3	$2.19K	Hold	19	–	–	﹤0.01%	616
2024 Q2	$2.62K	Hold	19	–	–	﹤0.01%	654
2024 Q1	$2.62K	Hold	19	–	–	﹤0.01%	637
2023 Q4	$2.5K	Hold	19	–	–	﹤0.01%	548
2023 Q3	$2.14K	Hold	19	–	–	﹤0.01%	567
2023 Q2	$1.79K	Hold	19	–	–	﹤0.01%	640
2023 Q1	$1.92K	Hold	19	–	–	﹤0.01%	622
2022 Q4	$2.27K	Hold	19	–	–	﹤0.01%	561
2022 Q3	$2.02K	Hold	19	–	–	﹤0.01%	601
2022 Q2	$1.85K	Hold	19	–	–	﹤0.01%	627
2022 Q1	$1.78K	Hold	19	–	–	﹤0.01%	666
2021 Q4	$1.62K	Hold	19	–	–	﹤0.01%	719
2021 Q3	$1.82K	Hold	19	–	–	﹤0.01%	640
2021 Q2	$1.85K	Hold	19	–	–	﹤0.01%	647
2021 Q1	$1.85K	Buy	19 +6	+46%	+$629	﹤0.01%	661
2020 Q4	$1.25K	Hold	13	–	–	﹤0.01%	684
2020 Q3	$1.25K	Hold	13	–	–	﹤0.01%	607
2020 Q2	$1.59K	Hold	13	–	–	﹤0.01%	529
2020 Q1	$1.13K	Hold	13	–	–	﹤0.01%	558
2019 Q4	$1.4K	Hold	13	–	–	﹤0.01%	499
2019 Q3	$1.17K	Buy	+13	New	+$1.22K	﹤0.01%	533
2019 Q2	–	Sell	-13	Closed	-$1.15K	–	1153
2019 Q1	$1.15K	Hold	13	–	–	﹤0.01%	508
2018 Q4	$928	Hold	13	–	–	﹤0.01%	567
2018 Q3	$1.6K	Hold	13	–	–	﹤0.01%	435
2018 Q2	$1.28K	Hold	13	–	–	﹤0.01%	472
2018 Q1	$1.08K	Buy	+13	New	+$1.1K	﹤0.01%	512
2016 Q4	–	Sell	-18	Closed	-$912	–	891
2016 Q3	$912	Hold	18	–	–	﹤0.01%	447
2016 Q2	$818	Hold	18	–	–	﹤0.01%	460
2016 Q1	$712	Hold	18	–	–	﹤0.01%	521
2015 Q4	$1.02K	Hold	18	–	–	﹤0.01%	386
2015 Q3	$716	Hold	18	–	–	﹤0.01%	501
2015 Q2	$860	Hold	18	–	–	﹤0.01%	434
2015 Q1	$715	Buy	+18	New	+$644	﹤0.01%	512

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's NBIX Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC increased its Neurocrine Biosciences (NBIX) stake by 20% in Q2 2026, buying an estimated $593 and bringing the position to 24 shares worth $4.04K. The position accounts for ﹤0.01% of the portfolio, ranked #641.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in NBIX in Q1 2015 and has held it in 40 quarters since. 205 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

RAFFA WEALTH MANAGEMENT, LLC held 24 shares of Neurocrine Biosciences worth $4.04K as of Q2 2026.
RAFFA WEALTH MANAGEMENT, LLC bought 4 Neurocrine Biosciences shares in Q2 2026, an estimated $593.
Neurocrine Biosciences made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #641 holding.
RAFFA WEALTH MANAGEMENT, LLC first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 40 quarters since.
205 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.